Clinical trials: Preventive Treatment of Migraine
Migraine Disorders
Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults
This study will evaluate the efficacy, safety and tolerability of prophylactic (preventative) treatment with BOTOX® (onabotulinumtoxinA) compared to topiramate in adults with chronic migraine.
- Trial name
- NCT02191579
- Testing
- onabotulinumtoxinA, Topiramate
- Where
- 32 sites in United States
- Volunteers
- 282 people
- Sponsor
- Allergan
Migraine Prophylaxis
Efficacy and Safety Study of E2007 in Migraine Prophylaxis
This was a 22-week, prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study that included a 4-week Baseline Phase at the beginning and a 4-week single-blind placebo Safety Phase at the end of…
- Trial name
- NCT00154063
- Testing
- E2007
- Where
- 9 sites in United States
- Volunteers
- 206 people
- Sponsor
- Eisai Inc.
Migraine, Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult participants with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg…
- Trial name
- NCT04041284
- Testing
- Fremanezumab
- Where
- 64 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Migraine in Children
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
- Trial name
- PROSPECT-2 (NCT04965675)
- Testing
- Eptinezumab
- Where
- 79 sites in United States, Argentina and 9 more
- Volunteers
- 285 people
- Sponsor
- H. Lundbeck A/S
Migraine
Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for Preventive Treatment of Migraine
The PERL Study will evaluate the safety and efficacy of a self-administered preventive treatment for migraine headache using combined occipital and trigeminal nerve stimulation (Relivion®).
- Trial name
- NCT05804396
- Testing
- Relivion®
- Sponsor
- Neurolief Ltd.
Migraine
Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis
The purpose of this study is to evaluate the efficacy of botulinum toxin type A (Dysport®) injections into pericranial muscles compared to placebo to prevent migraine attacks.
- Trial name
- NCT00301665
- Testing
- Botulinum toxin type A
- Where
- 9 sites in Czechia, Poland and 1 more
- Volunteers
- 138 people
- Sponsor
- Ipsen
Migraine, Headache
Comparing the Safety and Effectiveness of Topiramate With the Safety and Effectiveness of Amitriptyline in Preventing Migraine Headaches
The purpose of this study is to compare the effectiveness and safety of two treatment regimens in preventing migraines. The antidepressant amitriptyline has been used successfully to prevent migraine headaches.
- Trial name
- NCT00210821
- Testing
- topiramate
- Volunteers
- 347 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Migraine, Migraine Disorders
The Childhood and Adolescent Migraine Prevention Study
The purpose of this research study is to test two medicines for migraine prevention in children and adolescents.
- Conditions
- Migraine, Migraine Disorders, Headache
- Trial name
- CHAMP (NCT01581281)
- Testing
- Amitriptyline, Topiramate
- Where
- 35 sites in United States
- Volunteers
- 488 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Migraine
A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine
A pilot trial of triheptanoin, a natural compound able to promote anaplerotic mitochondrial metabolism, for the preventative treatment of migraine.
- Trial name
- TRIMI (NCT02784847)
- Testing
- Triheptanoin
- Volunteers
- 10 people
- Sponsor
- University of Liege
Migraine Disorders, Chronic Migraine
HD-EEG Connectivity Changes in Migraine Patients Undergoing Treatment With Anti-CGRP mAbs
Migraine is a leading cause of disability with an estimated prevalence of 12% in Europe. The headache field witnessed a breakthrough since the introduction of specific preventive therapies which proved effective and well…
- Conditions
- Migraine Disorders, Chronic Migraine, Episodic Migraine
- Trial name
- NCT06155123
- Testing
- Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
Migraine
Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine
Subjects enrolled at 2 investigative sites will complete 3 visits. Following Visit 1, during a 1-month Baseline Period, subjects will treat with their usual medication and document any warning signs (Prodrome pre-headache) that a…
- Trial name
- NCT00846495
- Testing
- topiramate, frovatriptan
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Clinvest
Migraine
A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist
The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill™) in adult participants with migraine who are taking a monoclonal antibody…
- Trial name
- NCT04294147
- Testing
- Galcanezumab, Erenumab
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
Migraine
Open-trial on the Prevention of Chronic Migraines With the CEFALY Device
The main objective of this study was to assess the safety and efficacy of the Cefaly® e-TNS device as a prophylactic treatment of chronic migraine in adult patients.
- Trial name
- NCT02342743
- Testing
- CEFALY
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Cefaly Technology
Treatment for Prevention of Chronic Migraine
A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
To assess the long-term safety and efficacy of erenumab.
- Trial name
- NCT02174861
- Testing
- Erenumab
- Where
- 65 sites in United States, Canada and 8 more
- Volunteers
- 609 people
- Sponsor
- Amgen
Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
The reason for this study is to see if the drug galcanezumab is safe and effective in participants with episodic migraine. The study will last about 53 weeks and may include up to 12 visits.
- Trial name
- PERSIST (NCT03963232)
- Testing
- Galcanezumab
- Where
- 40 sites in China, India and 1 more
- Volunteers
- 520 people
- Sponsor
- Eli Lilly and Company
Migraine, Migraine Disorder
Tai Chi and Acupuncture on Migraine Attack Prevention and Brain White Matter Changes
The goal of this clinical trial is to determine the effectiveness of Tai Chi training and acupuncture on the migraine attacks and structural brain changes in women with episodic migraine.
- Trial name
- NCT06967909
- Testing
- Tai Chi training, Acupuncture
- Where
- Hong Kong
- Volunteers
- 132 people
- Sponsor
- The Hong Kong Polytechnic University
Migraine
Transcranial Magnetic Stimulation in Episodic Migraine (Magnet-EM)
This study will assess the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) as new preventive treatment of migraine.
- Trial name
- Magnet-EM (NCT03556722)
- Testing
- Repetitive Transcranial Magnetic Stimulation.
- Where
- Malaysia
- Volunteers
- 76 people
- Sponsor
- Universiti Putra Malaysia
Migraine, Migraine With Aura
Effectiveness and Tolerability of Eptinezumab
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine
- Trial name
- TACHIS (NCT06409845)
- Testing
- Eptinezumab 100 or 300 mg ev
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- University of Florence
Chronic Migraine
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other…
- Trial name
- NCT06810505
- Testing
- Atogepant
- Where
- 66 sites in United States, Canada and 9 more
- Volunteers
- 420 people
- Sponsor
- AbbVie
Menstrual Migraine
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
- Trial name
- NCT06641466
- Testing
- Rimegepant, Standard of Care
- Where
- 123 sites in United States, Argentina and 13 more
- Volunteers
- 723 people
- Sponsor
- Pfizer